(Q38009719)

26 August 2017

Clinical perspective: statins and the liver--harmful or helpful? (English)

1 reference

26 August 2017

James H Lewis

1

1 reference

26 August 2017

12 May 2012

1 reference

Digestive Diseases and Sciences

26 August 2017

1 reference

26 August 2017

57

1 reference

26 August 2017

7

1 reference

26 August 2017

1754-1763

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-012-2207-3

26 August 2017

0 references

cites work

Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins in liver disease: a molehill, an iceberg, or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

The myth of statin-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Liver tests are irrelevant when prescribing statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Drug-induced liver injury associated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Liver function tests and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Use of statins in patients with liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Defining patient risks from expanded preventive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Suspected drug-induced liver fatalities reported to the WHO database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

HMG-CoA reductase inhibitors and coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins and liver toxicity: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Drug-induced acute liver failure: results of a U.S. multicenter, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

The role of hepatitis E virus testing in drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Important elements for the diagnosis of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Causality assessment of drug-induced hepatotoxicity: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Accuracy of hepatic adverse drug reaction reporting in one English health region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Review article: drug-induced liver injury in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Hepatic findings in long-term clinical trials of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Incidence of statin hepatotoxicity in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statin therapy and serum transaminases among a cohort of HCV-infected veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins improve ALT values in chronic hepatitis C patients with abnormal values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Targeting lipid metabolism in the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Fluvastatin inhibits hepatitis C replication in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Simvastatin protects against cholestasis-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Liver enzyme monitoring in patients treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Is there value in liver function test and creatine phosphokinase monitoring with statin use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Compliance to recommended liver function monitoring in patients on statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Cerivastatin, genetic variants, and the risk of rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2207-3

Yes! Statins can be given to liver patients

21 January 2018

1 reference

12 December 2020

Statins and elevated liver tests: what's the fuss?

1 reference

12 December 2020

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

An assessment of statin safety by hepatologists

1 reference

12 December 2020

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic

1 reference

12 December 2020

FDA adverse event reports on statin-associated rhabdomyolysis

1 reference

12 December 2020

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

1 reference

12 December 2020

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits

1 reference

12 December 2020

10.1007/S10620-012-2207-3

Identifiers

DOI

1 reference

PubMed ID

22581301

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22581301